文献速递慢性肾脏病肾血管病与高血压

醛固酮合酶抑制剂治疗CKD中未控制及难治性高血压:从基础到临床的评估

Aldosterone synthase inhibitors for uncontrolled and resistant hypertension in CKD: an assessment from bench to bedside.
PubMed 文献 · Nephrol Dial Transplant · 2026-01-01

本文综述了醛固酮合酶抑制剂(ASI)在慢性肾脏病(CKD)未控制及难治性高血压中的应用。CKD患者难治性高血压发生率高达40%,醛固酮失调参与钠潴留、炎症和纤维化。新一代选择性ASI在2/3期随机对照试验中显著降低诊室及动态血压,安全性可接受;早期2期试验显示ASI可降低CKD患者诊室血压并大幅减少白蛋白尿。

要点

  • CKD患者难治性高血压发生率高达40%,显著增加肾心风险。
  • 醛固酮失调通过钠潴留、炎症和纤维化促进靶器官损伤。
  • 新一代选择性ASI在2/3期试验中显著降低未控制及难治性高血压患者血压。

核心结论

  • 醛固酮合酶抑制剂是CKD未控制及难治性高血压的有前景治疗选择,可降低血压并减少白蛋白尿。

研究设计与样本

  • 综述评估醛固酮合酶抑制剂从基础到临床的证据,涵盖2期和3期随机对照试验。

主要发现

  • CKD患者难治性高血压发生率高达40%。
  • 新一代选择性ASI在2/3期随机对照试验中显著降低未控制及难治性高血压患者的诊室和动态血压,安全性可接受。
  • 早期2期试验显示ASI在CKD中降低诊室血压并大幅减少白蛋白尿。

关键数值与推荐

  • 螺内酯被推荐为难治性高血压的首选第四种药物,但在晚期CKD中因数据匮乏、高钾血症和肾功能下降风险而受限。

临床怎么用

  • 对于CKD合并未控制或难治性高血压患者,ASI可能成为新的治疗选择,尤其当螺内酯不耐受或禁忌时。

局限性

  • 螺内酯在晚期CKD中数据匮乏,高钾血症和肾功能下降发生率高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hypertension is highly prevalent in chronic kidney disease (CKD) and frequently remains uncontrolled despite high treatment rates; resistant hypertension occurs in up to 40% of CKD patients and markedly increases renal and cardiovascular risk. Aldosterone dysregulation plays a central role in this setting, contributing not only to sodium retention and volume expansion but also to inflammation, fibrosis and target-organ damage in the kidney, heart and vasculature. While spironolactone is recommended as the preferable fourth agent in resistant hypertension, its use in advanced CKD is limited by scarce data, and high rates of hyperkalemia and declining kidney function. Aldosterone synthase inhibitors (ASIs) are an emerging therapeutic class that directly suppress aldosterone production. Recent Phase 2 and 3 randomized controlled trials demonstrate that next-generation, selective ASIs produce clinically meaningful reductions in office and ambulatory blood pressure (BP) in patients with uncontrolled and resistant hypertension, with an acceptable safety profile. Early Phase 2 trials have also shown that ASIs are effective in lowering office BP levels in CKD with accompanying substantial reductions in albuminuria. This review examines the potential clinical benefits of aldosterone synthesis targeted therapy in the management of uncontrolled and resistant hypertension in CKD.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Theodorakopoulou MP, Iatridi F, Hecking M, et al. Aldosterone synthase inhibitors for uncontrolled and resistant hypertension in CKD: an assessment from bench to bedside. Nephrol Dial Transplant. 2026. PMID: 41591386. doi:10.1093/ndt/gfag013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。